Nutriband Inc. (NTRBW)

Market Cap	82.85M
Revenue (ttm)	2.02M
Net Income (ttm)	-6.85M
Shares Out	11.11M
EPS (ttm)	-0.69
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20
Open	1.650
Previous Close	1.640
Day's Range	1.430 - 1.650
52-Week Range	0.189 - 5.250
Beta	0.46
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 25, 2025

About NTRBW

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company’s lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Country: United States
• Stock Exchange: NASDAQ
• Ticker Symbol: NTRBW
• Website: https://www.nutriband.com

Financial Performance

In 2023, Nutriband's revenue was $2.09 million, an increase of 0.27% compared to the previous year's $2.08 million. Losses were -$5.49 million, 22.3% more than in 2022.